当前位置: X-MOL 学术Clin. Infect. Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Epidemiology and Outcomes of Hospitalizations With Invasive Aspergillosis in the United States, 2009-2013.
Clinical Infectious Diseases ( IF 11.8 ) Pub Date : 2018-08-16 , DOI: 10.1093/cid/ciy181
Marya D Zilberberg 1 , Brian H Nathanson 2 , Rachel Harrington 3 , James R Spalding 3 , Andrew F Shorr 4
Affiliation  

Background Though invasive aspergillosis (IA) complicates care of up to 13% of patients with immunocompromise, little is known about its morbidity and mortality burden in the United States. Methods We analyzed the Health Care Utilization Project's data from the Agency for Healthcare Research and Quality for 2009-2013. Among subjects with high-risk conditions for IA, IA was identified via International Classification of Diseases, Ninth Revision, Clinical Modification codes 117.3, 117.9, and 484.6. We compared characteristics and outcomes between those with (IA) and without IA (non-IA). Using propensity score matching, we calculated the IA-associated excess mortality and 30-day readmission rates, length of stay, and costs. Results Of the 66634683 discharged patients meeting study inclusion criteria, 154888 (0.2%) had a diagnosis of IA. The most common high-risk conditions were major surgery (50.1%) in the non-IA and critical illness (41.0%) in the IA group. After propensity score matching, both mortality (odds ratio, 1.43; 95% confidence interval, 1.36-1.51) and 30-day readmission (1.39; 1.34-1.45) rates were higher in the IA group. IA was associated with 6.0 (95% confidence interval, 5.7-6.4) excess days in the hospital and $15542 ($13869-$17215) in excess costs per hospitalization. Conclusions Although rare even among high-risk groups, IA is associated with increased hospital mortality and 30-day readmission rates, excess duration of hospitalization, and costs. Given nearly 40000 annual admissions for IA in the United States, the aggregate IA-attributable excess costs may reach $600 million annually.

中文翻译:

美国的侵袭性曲霉病住院流行病学和结局,2009-2013年。

背景技术尽管侵入性曲霉病(IA)使多达13%的免疫功能低下的患者的护理复杂化,但在美国对其发病率和死亡率负担知之甚少。方法我们分析了2009-2013年美国医疗保健研究与质量局(National Agency for Healthcare Research and Quality)提供的“医疗保健利用项目”的数据。在具有高危IA状况的受试者中,通过国际疾病分类,第九次修订,临床修改代码117.3、117.9和484.6来确定IA。我们比较了有(IA)和没有(IA)(非IA)的患者的特征和结果。使用倾向得分匹配,我们计算了IA相关的超额死亡率和30天的再入院率,住院时间和费用。结果在符合研究纳入标准的66634683名出院患者中,有154888名(0.2%)诊断为IA。最常见的高危疾病是非IA大手术(50.1%)和IA组危重疾病(41.0%)。倾向得分匹配后,IA组的死亡率(优势比,1.43; 95%置信区间,1.36-1.51)和30天再入院率(1.39; 1.34-1.45)均较高。IA与医院额外的6.0天(95%置信区间为5.7-6.4)和每天每次住院的额外费用$ 15542($ 13869- $ 17215)相关。结论尽管IA在高危人群中也很少见,但它与医院死亡率增加和30天再入院率,住院时间过长和费用相关。鉴于在美国每年有近40000个IA入学申请,IA造成的超额费用合计每年可能达到6亿美元。非IA组为1%),IA组为严重疾病(41.0%)。倾向得分匹配后,IA组的死亡率(优势比,1.43; 95%置信区间,1.36-1.51)和30天再入院率(1.39; 1.34-1.45)均较高。IA与医院额外的6.0天(95%置信区间为5.7-6.4)和每天每次住院的额外费用$ 15542($ 13869- $ 17215)相关。结论尽管IA在高危人群中也很少见,但IA与医院死亡率增加和30天再入院率,住院时间过长和费用相关。鉴于在美国每年有近40000个IA入学申请,IA造成的超额费用合计每年可能达到6亿美元。非IA组为1%),IA组为严重疾病(41.0%)。倾向得分匹配后,IA组的死亡率(奇数比,1.43; 95%置信区间,1.36-1.51)和30天再入院率(1.39; 1.34-1.45)均较高。IA与医院额外的6.0天(95%置信区间为5.7-6.4)和每天每次住院的额外费用$ 15542($ 13869- $ 17215)相关。结论尽管IA在高危人群中也很少见,但IA与医院死亡率增加和30天再入院率,住院时间过长和费用相关。鉴于在美国每年有近40000个IA入学申请,IA导致的超额费用合计每年可能达到6亿美元。IA组的51)和30天再入院率(1.39; 1.34-1.45)更高。IA与医院额外的6.0天(95%置信区间为5.7-6.4)和每天每次住院的额外费用$ 15542($ 13869- $ 17215)相关。结论尽管IA在高危人群中也很少见,但IA与医院死亡率增加和30天再入院率,住院时间过长和费用相关。鉴于在美国每年有近40000个IA入学申请,IA造成的超额费用合计每年可能达到6亿美元。IA组的51)和30天再入院率(1.39; 1.34-1.45)更高。IA与医院额外的6.0天(95%置信区间为5.7-6.4)和每天住院的额外费用15542美元(13869-17215美元)相关。结论尽管IA在高危人群中也很少见,但IA与医院死亡率增加和30天再入院率,住院时间过长和费用相关。鉴于在美国每年有近40000个IA入学申请,IA造成的超额费用合计每年可能达到6亿美元。IA与医院死亡率增加和30天再入院率,住院时间过长以及费用相关。鉴于在美国每年有近40000个IA入学申请,IA造成的超额费用合计每年可能达到6亿美元。IA与医院死亡率增加和30天再入院率,住院时间过长以及费用相关。鉴于在美国每年有近40000个IA入学申请,IA造成的超额费用合计每年可能达到6亿美元。
更新日期:2018-04-28
down
wechat
bug